Why the study?
Does ramipril prevent PKC activation and improve Ca2+ handling in a guinea pig model of pressure-overload heart failure?
Does ramipril prevent PKC activation and improve Ca2+ handling in a guinea pig model of pressure-overload heart failure?
ACE inhibition with ramipril attenuates PKC translocation and prevents downregulation of Ca2+ cycling proteins in pressure-overload hypertrophy, providing a molecular mechanism for its benefits in heart failure.
Answers are grounded in this paper and cite their sources.
Ramipril's PKC and Ca2+ effects in guinea pig HF are hypothesis-generating; leaves open translation to human pressure-overload disease.
We tested the hypothesis that activation of protein kinase C (PKC) isoforms in pressure-overload heart failure was prevented by angiotensin-converting enzyme (ACE) inhibition, resulting in normalization of cardiac sarcoplasmic reticulum (SR) Ca2+ ATPase (SERCA) 2a and phospholamban protein levels and improvement in intracellular Ca2+ handling. Aortic-banded and control guinea pigs were given ramipril (5 mg. kg-1. day-1) or placebo for 8 wk. Ramipril-treated banded animals had lower left ventricular (LV) and lung weight, improved survival, increased isovolumic LV mechanics, and improved cardiomyocyte Ca2+ transients compared with placebo-treated banded animals. This was associated with maintenance of SERCA2a and phospholamban protein expression. Translocation of PKC-alpha and -epsilon was increased in placebo-treated banded guinea pigs compared with controls and was attenuated significantly by treatment with ramipril. We conclude that ACE inhibition attenuates PKC translocation and prevents downregulation of Ca2+ cycling protein expression in pressure-overload hypertrophy. This represents a mechanism for the beneficial effects of this therapy on LV function and survival in heart failure.
No takes yet. Share an insight, caveat, or question.
Takeishi et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: